Fannin UK, a leading provider of medical devices, has launched mAI Companion®, a real-time medical AI solution developed by Medi-Globe to assist physicians in detecting pancreatic lesions during endoscopic ultrasound (EUS). mAI Companion addresses one of the deadliest and most difficult-to-detect cancers, where earlier identification can dramatically improve patient outcomes.
Developed through a multi-year collaboration with IHU Strasbourg, mAI Companion has received MDR CE Mark certification, making it the first AI assistant for pancreatic EUS of its kind to be approved for clinical use in the UK.
Pancreatic cancer remains one of the deadliest malignancies worldwide, and early detection can significantly improve survival. EUS provides high‑resolution, close‑up imaging and allows targeted biopsy confirmation - but the technique demands years of experience, and subtle lesions can still be difficult to detect.
mAI Companion functions as an intelligent “second set of eyes” during EUS, automatically analysing the head, body, and tail of the pancreas in real time to highlight solid and cystic lesions that may otherwise go unnoticed. The expected result: greater diagnostic confidence, more systematic exams, and fewer missed findings supporting earlier identification of pancreatic lesions including stages when treatment options and survival outcomes are significantly improved.
AI performance depends on data quality. mAI Companion was created in collaboration with leading European expert centres and trained on hundreds of real‑patient EUS videos containing more than five million expert‑annotated images. Each annotation was validated by experienced endoscopists, enabling the software to act like a trusted expert advisor beside the clinician.
The MDR CE‑Marked mAI Companion is expected to deliver practical value across all levels of clinical practice - improving confidence, consistency, and clinical quality in pancreatic EUS:
- Experienced Endoscopists: Greater reassurance in complex or ambiguous cases with real‑time AI support by providing an extra set of eyes e.g. for small, hard‑to‑spot lesions.
- Departments & Teams: Standardised EUS quality across operators, reduced variability, and faster development of junior staff.
- Hospitals & Institutions: Stronger reputation, academic prestige and leadership in pancreatic cancer care.
Together, these benefits drive more confident exams, more consistent results, and better patient outcomes - reinforcing trust and institutional excellence in pancreatic EUS. Earlier and more reliable lesion detection supports faster diagnosis, earlier treatment decisions, and ultimately improved patient pathways in a disease where time is critical.
Visit: www.fannin.eu
